CMG Ingredient Spotlight March 2026: NMN
Welcome to the CMG Ingredient Spotlight for March 2026. This edition focuses on nicotinamide mononucleotide (NMN), a bioactive nucleotide that has attracted considerable attention in recent years for its potential as a therapeutic agent in addressing age-related health conditions. March has also been a productive month for NMN, with several key articles published. In this […]
Article: A Spotlight on Nicotinamide Mononucleotide (NMN)
In March, a journal article on NMN by Dr Brad McEwen PhD was published, titled “A Spotlight on Nicotinamide Mononucleotide (NMN)”. It was published in the peer-reviewed journal Australasian Journal of Natural Medicine. This article discussed the preclinical research of NMN, including enhancing NAD+ biosynthesis, increasing intracellular NAD+ levels, and improving mitochondrial bioenergetics, cellular energy […]
Welcome to 2026
Happy New Year and Welcome to 2026. After the break, CMG has opened its doors to the new year and is in full swing. We are excited for 2026, the year of innovation. Throughout 2025, we saw customers expand existing product ranges, launch exciting new innovations, and secure placements in new retail stores. These achievements […]
CMG Breaking News: Nicotinamide mononucleotide (NMN) now permitted in Australia
Welcome to CMG Breaking News: Nicotinamide mononucleotide (NMN) now permitted in Australia Nicotinamide mononucleotide (NMN) is now a permitted ingredient for Listed Medicines (AUST L) and Assessed Listed Medicines (AUST L(A)) in Australia. Introduction Nicotinamide mononucleotide (NMN) is a bioactive nucleotide that has amassed significant attention in recent years due to its potential as a […]